CLASP study shows sustained MR reduction and positive left ventricular remodeling accompanied by high survival and low HF Hospitalization rate
**Study design & baseline parameters**

**Study Design**: Multicenter, multinational, prospective, single-arm study

- **Total patients**: 124
- **FMR**: 69% | **DMR**: 31%
- **Baseline NYHA Class III/IV**: 60.2%
- **MR severity ≥3+**: 100%
- **Mean age**: 74.9 years
- **PIASA EROA**: 0.38 ± 0.15 cm²
- **Regurgitant volume**: 57.3 ± 19.7 ml
- **Mean vena contracta width, A-P**: 6.3 ± 1.4 mm

---

### Robust and significant MR Reduction

<table>
<thead>
<tr>
<th>MR ≤2+ (%)</th>
<th>Baseline</th>
<th>30 Days</th>
<th>1 Year</th>
<th>2 Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>N = 124</td>
<td>N = 117</td>
<td>N = 85</td>
<td>N = 36</td>
</tr>
<tr>
<td>97%</td>
<td>46%</td>
<td>20%</td>
<td>97%</td>
<td>2.2%</td>
</tr>
<tr>
<td>80%</td>
<td>53%</td>
<td>15%</td>
<td>77%</td>
<td>15%</td>
</tr>
<tr>
<td>60%</td>
<td>15%</td>
<td>15%</td>
<td>78%</td>
<td>78%</td>
</tr>
</tbody>
</table>

**Overall**

- Severe (4+)
- Moderate-Severe (3+)
- Mild-Moderate (2+)
- Mild (1+)
- None/Trace (0)

---

### High Survival Rate and Low Heart Failure Hospitalization rates

**80% Survival**

- **Freedom from Mortality (%)**
  - Overall: 97.3 ± 2.7
  - FMR: 91.2 ± 2.7
  - DMR: 88.3 ± 2.7
  - Overall: 94.3 ± 3.9
  - FMR: 90.3 ± 4.2
  - DMR: 84.3 ± 3.6

**Freedom from HF Rehospitalization (%)**

**85% Reduction in HF hospitalization rate**

- **Annualized HF hospitalization rate**
  - 1 year pre-procedure: 1.16
  - 1 year post-procedure CEC-adjudicated: 0.2
  - 2 years post-procedure site-reported: 0.17

**84% Freedom from HF rehospitalization**

- **Overall**: 100 ± 0.0,
- **FMR**: 97.3 ± 2.7,
- **DMR**: 97.3 ± 2.7
Positive left ventricular remodeling in the overall population over time

Conclusions:

The PASCAL transcatheter valve repair system achieved high rates of 2-year survival with significant reduction in annualized HF hospitalization, thanks to durable and sustained MR reduction with evidence of LV reverse remodeling and significant improvement in functional status.1
PASCAL Repair System

In your hands we can create amazing.

See what we’re making possible.
Scan the QR code with your phone or visite now: Edwards.com/PASCAL.

* New York Heart Association, Functional Classification (NYHA)


For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).

Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards, Edwards Lifesciences, the stylized E logo, Edwards PASCAL, CLASP, and PASCAL are trademarks or service marks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

© 2021 Edwards Lifesciences Corporation. All rights reserved. PP--EU-2424 v1.0

Edwards Lifesciences • Route de l’Etraz 70, 1260 Nyon, Switzerland • edwards.com